



UK FemSeven (estradiol +/- levonorgestrel) Stock Update

FemSeven Conti[®] (estradiol/levonorgestrel) available now via Alliance Healthcare

January 2021

Theramex holds the marketing authorisation for FemSeven 50, 75 and 100[®] (estradiol), FemSeven Conti[®] (estradiol/levonorgestrel) and FemSeven Sequi[®] (estradiol/levonorgestrel) in the UK and Europe since acquiring these products from Teva Pharmaceuticals Ltd on 1st February 2018.

Non-patient-safety related quality issues were brought to our attention resulting in the gradual withdrawal of the FemSeven[®] portfolio from the market.

We have since been working diligently to fix these issues and are pleased confirm that the entire FemSeven[®] portfolio of products will be returning in 2021 commencing with **FemSeven Conti[®] which is available now from Alliance Healthcare.**

We anticipate that the rest of the FemSeven[®] portfolio will be available by mid-2021 and we will continue keep health care professionals informed of any changes. We would like to thank both patients and prescribers for their continued patience.

Further Information

Patients who have any questions with regards to their treatment options should speak to their healthcare professional.

For pharmacists and healthcare professionals who wish to place orders for FemSeven Conti[®], please contact Alliance Healthcare via your usual channels.